Mark S Sulkowski

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. doi request reprint Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, 600 North Wolfe Street, 1830 Building, Baltimore, MD 21287, USA
    Ann Intern Med 159:86-96. 2013
  2. doi request reprint Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
    Mark Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Lancet Infect Dis 13:597-605. 2013
  3. doi request reprint Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial
    Mark S Sulkowski
    Johns Hopkins University, Baltimore, MD, USA
    Hepatology 57:2143-54. 2013
  4. doi request reprint Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
    Mark S Sulkowski
    Viral Hepatitis Center, John Hopkins University School of Medicine, Baltimore, MD, USA
    Hepatology 57:2155-63. 2013
  5. pmc Current management of hepatitis C virus infection in patients with HIV co-infection
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA
    J Infect Dis 207:S26-32. 2013
  6. doi request reprint Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287 0003, USA
    Hepatology 57:974-84. 2013
  7. doi request reprint HCV therapy in HIV-infected patients
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Liver Int 33:63-7. 2013
  8. doi request reprint Hepatitis C virus-human immunodeficiency virus coinfection
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Liver Int 32:129-34. 2012
  9. pmc Hepatic profile analyses of tipranavir in Phase II and III clinical trials
    Jaromir Mikl
    SUNY at Albany, School of Public Health, Rensselaer NY, USA
    BMC Infect Dis 9:203. 2009
  10. doi request reprint Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 0003, USA
    Gastroenterology 139:1602-11, 1611.e1. 2010

Detail Information

Publications67

  1. doi request reprint Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, 600 North Wolfe Street, 1830 Building, Baltimore, MD 21287, USA
    Ann Intern Med 159:86-96. 2013
    ..Its safety and efficacy in patients with HCV and HIV-1 are unknown...
  2. doi request reprint Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
    Mark Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Lancet Infect Dis 13:597-605. 2013
    ..We aimed to assess efficacy and safety of triple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases rates of SVR in patients with HCV alone...
  3. doi request reprint Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial
    Mark S Sulkowski
    Johns Hopkins University, Baltimore, MD, USA
    Hepatology 57:2143-54. 2013
    ..The 120 and 240 mg QD doses are currently undergoing phase 3 evaluation. (HEPATOLOGY 2013;57:2143-2154)...
  4. doi request reprint Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
    Mark S Sulkowski
    Viral Hepatitis Center, John Hopkins University School of Medicine, Baltimore, MD, USA
    Hepatology 57:2155-63. 2013
    ..Conclusion: Faldaprevir 240 mg QD with PegIFN/RBV was safe and tolerable and produced substantial SVR rates in prior null and partial responders. The 240 mg QD dose is currently undergoing phase 3 evaluation...
  5. pmc Current management of hepatitis C virus infection in patients with HIV co-infection
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA
    J Infect Dis 207:S26-32. 2013
    ..As such, these HCV PI-based regimens have emerged as the standard for the treatment of HCV genotype 1 infection in carefully selected HIV-infected patients...
  6. doi request reprint Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287 0003, USA
    Hepatology 57:974-84. 2013
    ..Serious and life-threatening adverse events (AEs) and discontinuations due to AEs among BOC-treated patients did not differ by EPO use...
  7. doi request reprint HCV therapy in HIV-infected patients
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Liver Int 33:63-7. 2013
    ....
  8. doi request reprint Hepatitis C virus-human immunodeficiency virus coinfection
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Liver Int 32:129-34. 2012
    ..Accordingly, these agents may be recommended for HCV treatment in carefully selected HIV-infected persons...
  9. pmc Hepatic profile analyses of tipranavir in Phase II and III clinical trials
    Jaromir Mikl
    SUNY at Albany, School of Public Health, Rensselaer NY, USA
    BMC Infect Dis 9:203. 2009
    ....
  10. doi request reprint Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 0003, USA
    Gastroenterology 139:1602-11, 1611.e1. 2010
    ..We investigated the relationships among treatment outcomes, anemia, and their management with RBV dose reduction and/or erythropoiesis-stimulating agents (ESAs)...
  11. ncbi request reprint Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 21:2209-16. 2007
    ....
  12. ncbi request reprint Viral hepatitis and HIV coinfection
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, 600 North Wolfe Street, 1830 Building, Room 448, Baltimore, MD 21287, USA
    J Hepatol 48:353-67. 2008
    ..Current approaches to management of HIV-infected persons coinfected with HBV or HCV are discussed in this review...
  13. doi request reprint Management of hepatic complications in HIV-infected persons
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287, USA
    J Infect Dis 197:S279-93. 2008
    ..Despite the complexity and potential for antiretroviral-associated hepatotoxicity, ART usually is safe for patients with viral hepatitis coinfection, and, in some cases, treatment for HIV infection may be beneficial for the liver...
  14. doi request reprint Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
    Mark S Sulkowski
    Viral Hepatitis Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Nat Rev Gastroenterol Hepatol 8:212-23. 2011
    ....
  15. pmc Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus
    Tinsay A Woreta
    The Johns Hopkins Hospital University School of Medicine, Baltimore, Maryland 21287, USA
    Gastroenterology 140:809-17. 2011
    ..We prospectively examined the natural history of steatosis in patients coinfected with HIV and HCV who attended an urban HIV clinic...
  16. pmc Vitamin D deficiency and its relation to bone mineral density and liver fibrosis in HIV-HCV coinfection
    Diala El-Maouche
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Antivir Ther 18:237-42. 2013
    ..Fractures and cirrhosis are major causes of morbidity and mortality among HIV-HCV-coinfected individuals. It is not known whether vitamin D deficiency is associated with these outcomes...
  17. pmc Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV
    Berkeley N Limketkai
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    JAMA 308:370-8. 2012
    ..Human immunodeficiency virus (HIV) accelerates hepatitis C virus (HCV) disease progression; however, the effect of liver disease stage and antiviral therapy on the risk of clinical outcomes is incompletely understood...
  18. pmc Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution
    Ashwin Balagopal
    Division of Infectious Diseases, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    AIDS 23:2397-404. 2009
    ..Although hepatic macrophages (Kupffer cells) clear most microbial translocation products and can be infected by HIV, their fate in HIV progression has not been carefully investigated...
  19. ncbi request reprint Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
    Mark S Sulkowski
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 18:2277-84. 2004
    ....
  20. ncbi request reprint The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    J Acquir Immune Defic Syndr 33:577-84. 2003
    ..DESIGN Retrospective cohort analysis of 1230 persons on their first HAART regimen who had at least 1 random glucose measurement before and during antiretroviral therapy...
  21. ncbi request reprint The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD 21205 0003, USA
    Hepatology 41:123-31. 2005
    ..Recognition of bridging fibrosis and cirrhosis in some but not most patients underscores the importance of identifying and treating liver disease in HIV/HCV coinfected persons...
  22. ncbi request reprint Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus
    Mark S Sulkowski
    Division of Infectious Diseases Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 19:585-92. 2005
    ....
  23. ncbi request reprint Hepatitis C and progression of HIV disease
    Mark S Sulkowski
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St, Room 448, Baltimore, MD 21287 0003, USA
    JAMA 288:199-206. 2002
    ..Conflicting reports exist regarding the effect of hepatitis C virus (HCV) on the progression of human immunodeficiency virus (HIV) disease...
  24. ncbi request reprint Needlestick transmission of hepatitis C
    Mark S Sulkowski
    Johns Hopkins School of Medicine, 424 N Bond St, Baltimore, MD 21231, USA
    JAMA 287:2406-13. 2002
    ..These data underscore the importance of identifying persons with acute HCV infection and promptly referring them to experienced clinicians who can provide updated counseling and treatment...
  25. ncbi request reprint Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 35:464-72. 2004
    ..In conclusion, SVR was achieved in 19% of HIV/HCV coinfected subjects treated with daily IFN plus RBV, but the effectiveness of therapy was substantially diminished by relatively high rates of treatment-related toxicity...
  26. pmc Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection
    Diala El-Maouche
    Johns Hopkins School of Medicine, Baltimore, MD, USA
    J Hepatol 55:770-6. 2011
    ..To evaluate the prevalence and risk factors for low bone mineral density (BMD) in persons co-infected with HIV and Hepatitis C...
  27. ncbi request reprint Treatment of chronic hepatitis C: a systematic review
    Geetanjali Chander
    Department of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hepatology 36:S135-44. 2002
    ..Thus, the combination of peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment...
  28. pmc Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons
    David L Thomas
    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    Clin Infect Dis 54:979-83. 2012
    ..Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons...
  29. pmc Stability of liver fibrosis among HCV-infected injection drug users
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Antivir Ther 17:813-21. 2012
    ....
  30. ncbi request reprint Hepatitis C virus infection in HIV-infected patients
    Mark S Sulkowski
    Division of Infectious Diseases, Johns Hopkins Medical Institutions, 1830 East Monument Street, Room 319, Baltimore, MD 21287, USA
    Curr HIV/AIDS Rep 1:128-35. 2004
    ..This review focuses on the epidemiology, natural history, and management of HCV in the HIV-infected patient...
  31. ncbi request reprint Treatment algorithm for the management of hepatitis C in HIV-coinfected persons
    Mark S Sulkowski
    Johns Hopkins Medical Institutions, 1830 East Monument Street, Room 319, Baltimore, MD 21287 0003, USA
    J Hepatol 44:S49-55. 2006
    ..Although, the available data has led to consensus among experts regarding the need to medically manage HCV disease in HIV-infected persons, uncertainty remains regarding the best treatment algorithm for coinfected patients...
  32. doi request reprint Detection of liver disease in injection drug users
    David L Thomas
    Department of Medicine, Johns Hopkins School of Medicine, 1503 East Jefferson Street, Baltimore, MD 21231, USA
    J Addict Dis 27:19-24. 2008
    ....
  33. ncbi request reprint Anemia in the treatment of hepatitis C virus infection
    Mark S Sulkowski
    Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Clin Infect Dis 37:S315-22. 2003
    ..Higher RBV doses and adherence to HCV therapy have been associated with higher sustained virologic response (SVR) rates. Maintenance of RBV dose with epoetin alfa may improve adherence, thereby affecting SVR...
  34. pmc Racial differences in hepatitis C treatment eligibility
    Michael T Melia
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hepatology 54:70-8. 2011
    ..001). Blacks were more likely to be ineligible due to neutropenia (14% versus 3%, P < 0.001), anemia (7% versus 4%, P = 0.02), elevated glucose (8% versus 3%, P < 0.001), and elevated creatinine (5% versus 1%, P < 0.001)...
  35. ncbi request reprint Hepatitis C in the HIV-infected patient
    Mark S Sulkowski
    Viral Hepatitis Section, Division of Infectious Diseases, Johns Hopkins School of Medicine, Suite 102, 424 North Bond Street, Baltimore, MD 21231, USA
    Clin Liver Dis 7:179-94. 2003
    ..Future efforts should include prospective studies that demonstrate the natural history and optimal management of HIV/HCV-coinfected patients, including the feasibility of liver transplantation...
  36. pmc Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors
    Maria Salgado
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    AIDS 25:385-7. 2011
    ..Thus, it appears that this SNP is not associated with the elite control of HIV-1 infection...
  37. ncbi request reprint Hepatitis C in the HIV-Infected Person
    Mark S Sulkowski
    Division of Infections Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 448, Baltimore, MD 21287 0003, USA
    Ann Intern Med 138:197-207. 2003
    ..Such efforts will help to eliminate HCV-related liver disease as an emerging threat to HIV-infected persons...
  38. ncbi request reprint Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections
    Mark S Sulkowski
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD21205, USA
    Hepatology 35:182-9. 2002
    ..Severe hepatotoxicity occurs throughout the course of NNRTI therapy and is more common among patients prescribed nevirapine, those coinfected with HCV or HBV, and those coadministered protease inhibitors...
  39. ncbi request reprint Management of the hematologic complications of hepatitis C therapy
    Mark S Sulkowski
    Viral Hepatitis Center, Johns Hopkins University School of Medicine, 600 North Wolfe Street, 1830 Building, Room 448, Baltimore, MD 21287, USA
    Clin Liver Dis 9:601-16, vi. 2005
    ..Consensus guidelines are in place for treating chronic hepatitis C virus infection. This article highlights some of the hematologic complications of hepatitis C therapy. Management options are presented...
  40. doi request reprint Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study
    Michael T Melia
    Johns Hopkins University School of Medicine, Baltimore, Maryland
    Clin Infect Dis 58:960-9. 2014
    ..Clinicians should be aware of their patients' absolute lymphocyte counts during peg-IFN/RBV therapy; peg-IFN dose reductions may be a consideration in patients with significant lymphocytopenia (<0.5 × 10(9) cells/L). ..
  41. doi request reprint Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs
    Monica A Konerman
    Johns Hopkins Hospital University School of Medicine, Baltimore, MD
    Hepatology 59:767-75. 2014
    ..Hepatology 2014;59:767-775). ..
  42. ncbi request reprint Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 0003, USA
    Clin Infect Dis 38:S90-7. 2004
    ..Clearly, further research is needed to define the interaction of PIs and chronic viral hepatitis in the development of DILI...
  43. ncbi request reprint A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, USA
    AIDS 19:S179-89. 2005
    ....
  44. ncbi request reprint Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment
    Mark S Sulkowski
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Infect Dis 40:S263-9. 2005
    ..Solutions to the problem of HCV infection among IDUs must account for these facts...
  45. ncbi request reprint Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors
    Mark S Sulkowski
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Semin Liver Dis 23:183-94. 2003
    ..Further research is needed to understand the etiopathogenesis of PI-associated liver injury, particularly among patients with hepatitis B or C infection...
  46. ncbi request reprint Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness
    Mark S Sulkowski
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287 0003, USA
    AIDS 19:S8-12. 2005
  47. ncbi request reprint Specific targeted antiviral therapy for hepatitis C
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, 600 North Wolfe Street, 1830 Building, Room 448, Baltimore, MD 21287, USA
    Curr Gastroenterol Rep 9:5-13. 2007
    ..This review focuses on hepatitis C protease and polymerase inhibitors that have progressed to phase II clinical development, foreshadowing the era of STAT-Cs...
  48. pmc Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events
    Christopher J Hoffmann
    Aurum Institute for Health Research, Johannesburg, South Africa
    AIDS 22:67-74. 2008
    ..To describe the safety and tolerability of zidovudine, lamivudine, and efavirenz in a low-income setting...
  49. pmc Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons
    Todd T Brown
    Johns Hopkins School of Medicine, USA
    AIDS 24:811-7. 2010
    ..To evaluate the relationship between regional body composition and liver disease (fibrosis or steatosis) in HIV/HCV co-infected individuals...
  50. ncbi request reprint Antiretroviral-associated liver injury
    Anthony O Ogedegbe
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 448, Baltimore, MD 21287, USA
    Clin Liver Dis 7:475-99. 2003
    ....
  51. ncbi request reprint Therapy insight: Management of hepatitis C in patients coinfected with HIV
    Mark S Sulkowski
    Viral Hepatitis Center, Johns Hopkins Medical Institutions, Baltimore, MD 21287 0003, USA
    Nat Clin Pract Gastroenterol Hepatol 2:223-31. 2005
    ..This review considers the management of HCV infection in HIV-infected patients...
  52. ncbi request reprint The HIV-coinfected patient: managing viral hepatitis
    Mark S Sulkowski
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 45:S36-7. 2007
  53. ncbi request reprint Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Clin Infect Dis 41:1035-40. 2005
  54. ncbi request reprint Needlestick injuries among surgeons in training
    Martin A Makary
    Center for Outcomes Research, Department of Surgery, Health Policy and Management, Johns Hopkins University School of Medicine, Quality and Safety Research Group, Baltimore 21231, USA
    N Engl J Med 356:2693-9. 2007
    ..Surgeons in training are at high risk for needlestick injuries. The reporting of such injuries is a critical step in initiating early prophylaxis or treatment...
  55. doi request reprint Predictors of consent to pharmacogenomics testing in the IDEAL study
    Alison B Jazwinski
    aDepartment of Medicine, Division of Gastroenterology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina bDepartment of Medicine, Division of Gastroenterology Hepatology, Henry Ford Hospital, Detroit, Michigan cDepartment of Medicine, Alamo Medical Research, San Antonio, Texas dMerck Research Laboratories, Department of Infectious Disease, Whitehouse Station, New Jersey eDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA fDepartment of Gastroenterology, St Vincent s Hospital, University of Melbourne, Melbourne, Victoria, Australia
    Pharmacogenet Genomics 23:619-23. 2013
    ..Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia...
  56. ncbi request reprint Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa
    Douglas T Dieterich
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Am J Gastroenterol 98:2491-9. 2003
    ....
  57. ncbi request reprint Regression of splenic lymphoma after treatment of hepatitis C virus infection
    Leisha A Emens
    N Engl J Med 347:2168-70; author reply 2168-70. 2002
  58. ncbi request reprint Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person
    Mark S Sulkowski
    Hepatology 39:906-8. 2004
  59. ncbi request reprint Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:901-8. 2006
    ..05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-alpha...
  60. ncbi request reprint Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA
    AIDS 20:2361-9. 2006
    ..To evaluate predictors and trends of referral for hepatitis C virus (HCV) care, clinic attendance and treatment in an urban HIV clinic...
  61. ncbi request reprint Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    J Clin Virol 36:283-91. 2006
    ..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
  62. ncbi request reprint A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:35-45. 2006
    ..These results support further clinical studies of albumin-IFN-alpha for the treatment of patients with chronic hepatitis C...
  63. ncbi request reprint Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial
    Mark S Sulkowski
    J Acquir Immune Defic Syndr 39:504-6. 2005
  64. ncbi request reprint Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    Paul J Pockros
    Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 40:1450-8. 2004
    ..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy...
  65. ncbi request reprint Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection
    Richard K Sterling
    Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298, USA
    Semin Liver Dis 24:61-8. 2004
    ....
  66. ncbi request reprint Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 126:1302-11. 2004
    ..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...
  67. ncbi request reprint Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study
    Norbert Brau
    Bronx Veterans Affairs VA Medical Center, Infectious Disease Section 111F, 130 West Kingsbridge Road, Bronx, NY 10468, USA
    J Hepatol 47:527-37. 2007
    ..HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC)...